Strategic Exit: Standard BioTools Cashes Out, But Stays Connected
This acquisition is also a milestone for Standard BioTools, which bought SomaLogic just 18 months ago. CEO Michael Egholm said the company successfully restructured and elevated SomaLogic into a category leader in proteomics.
“The transaction reflects the transformation we’ve achieved,” said Egholm. “This deal lets us participate in SomaLogic’s future upside while reallocating resources strategically.”
Proteomics Meets Sequencing: A Scientific Power Play
Proteomics, the study of proteins and their functions within biological systems, is considered the next frontier in precision medicine. By combining SomaLogic’s technology with Illumina’s NGS capabilities, the deal is poised to slash the time and cost of research, making disease diagnostics faster, more accurate, and scalable.
Illumina’s multiomics strategy — aimed at integrating genomic, transcriptomic, and proteomic data — took center stage in 2024, and this acquisition cements its seriousness in that arena.
